Literature DB >> 16168516

Hepatic steatosis and insulin resistance: does etiology make a difference?

Amedeo Lonardo1, Silvia Lombardini, Federica Scaglioni, Lucia Carulli, Matteo Ricchi, Dorval Ganazzi, Luigi Elio Adinolfi, Giuseppe Ruggiero, Nicola Carulli, Paola Loria.   

Abstract

BACKGROUND/AIMS: To ascertain whether the etiology of hepatic steatosis modulates insulin resistance (IR) and to determine the predictors of IR.
METHODS: We studied IR through HOMA IR in 146 subjects, 99 of whom had ultrasonographic and/or histologic steatosis. Twenty-two had familial heterozygous hypobetalipoproteinemia (FHBL), 48 had non-alcoholic fatty liver disease (NAFLD), 34 HCV infection (17 with HCV1b, 17 with HCV3a) and 42 were healthy controls without steatosis.
RESULTS: Steatosis was present in 77.3% of FHBL and, by enrolment criteria, in all NAFLD and HCV cases. Overall HOMA-IR correlated with BMI and GGT (P<0.01). FHBL and healthy groups had similar HOMA-IR and GGT values, whereas higher levels were observed in HCV and NAFLD. HCV3a and FHBL patients were hypolipidemic. HOMA-IR was similar in FHBL patients and controls and lower than in HCV and NAFLD. FHBL patients had a high extent of steatosis, similar to that observed in HCV3a, but lower grading and staging than NAFLD and HCV. At multivariate analysis, steatosis and GGT predicted HOMA-IR.
CONCLUSIONS: Data suggest that not all hepatic fat associates with IR. FHBL patients, for some aspects, resemble HCV3a infection, possibly suggesting a shared steatogenic mechanism. Among steatotic patients serum GGT levels is the independent predictor of IR.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16168516     DOI: 10.1016/j.jhep.2005.06.018

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  30 in total

1.  Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?

Authors:  Stefano Ballestri; Amedeo Lonardo; Luisa Losi; Elisa Pellegrini; Marco Bertolotti; Paola Loria
Journal:  Intern Emerg Med       Date:  2008-07-17       Impact factor: 3.397

Review 2.  Chronic HCV infection and inflammation: Clinical impact on hepatic and extra-hepatic manifestations.

Authors:  Rosa Zampino; Aldo Marrone; Luciano Restivo; Barbara Guerrera; Ausilia Sellitto; Luca Rinaldi; Ciro Romano; Luigi E Adinolfi
Journal:  World J Hepatol       Date:  2013-10-27

Review 3.  Hypobetalipoproteinemia and abetalipoproteinemia.

Authors:  Francine K Welty
Journal:  Curr Opin Lipidol       Date:  2014-06       Impact factor: 4.776

4.  The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.

Authors:  Viola Weich; Eva Herrmann; Tje Lin Chung; Christoph Sarrazin; Holger Hinrichsen; Peter Buggisch; Tilman Gerlach; Hartwig Klinker; Ulrich Spengler; Alexandra Bergk; Stefan Zeuzem; Thomas Berg
Journal:  J Gastroenterol       Date:  2011-09-13       Impact factor: 7.527

5.  Effect of soy protein supplementation in patients with chronic hepatitis C: a randomized clinical trial.

Authors:  Lucivalda P M Oliveira; Rosangela P de Jesus; Ramona S S B Boulhosa; Carlos Mauricio C Mendes; Maria Cecilia Gnoatto; Denise C Lemaire; Maria Betania P Toralles; Lourianne N Cavalcante; Andre C Lyra; Luiz G C Lyra
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

6.  Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia.

Authors:  Maartje E Visser; Fatima Akdim; Diane L Tribble; Aart J Nederveen; T Jesse Kwoh; John J P Kastelein; Mieke D Trip; Erik S G Stroes
Journal:  J Lipid Res       Date:  2009-12-14       Impact factor: 5.922

Review 7.  Dysmetabolic changes associated with HCV: a distinct syndrome?

Authors:  Amedeo Lonardo; Paola Loria; Nicola Carulli
Journal:  Intern Emerg Med       Date:  2008-02-15       Impact factor: 3.397

8.  Liver and diabetes. A vicious circle.

Authors:  Paola Loria; Amedeo Lonardo; Frank Anania
Journal:  Hepatol Res       Date:  2013-01       Impact factor: 4.288

Review 9.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

Review 10.  Effect of Intragastric Balloons on Liver Enzymes: A Systematic Review and Meta-Analysis.

Authors:  Violeta B Popov; Christopher C Thompson; Nitin Kumar; Maria M Ciarleglio; Yanhong Deng; Loren Laine
Journal:  Dig Dis Sci       Date:  2016-05-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.